MetaCap

Neogen (NEOG) vs Achieve Life Sciences (QUIT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Neogen is the larger company by market cap ($2.30 billion vs $573.2 million), about 4.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

NEOG-11.12%QUIT-25.87%
+20%-4%-28%
Aug 17, 20261 yearNov 20, 2026
NEOG-11.72%QUIT-30.41%
+17%-8%-33%
Aug 17, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

NEOG versus QUIT key metrics
MetricNEOGQUIT
Share price$10.55$5.56
Market cap$2.30B$573.25M
1-day change-2.76%-5.28%
YTD return+50.93%—
1-year return+84.44%—
5-year return-74.39%—
Forward P/E23.44—
EPS (TTM)$-0.26$-1.71
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$870.40M—
Revenue growth (YoY)-2.72%—
Net income (latest FY)$-7.90M$-54.65M
Gross margin46.93%—
Operating margin-2.48%—
Net margin-0.91%—
52-week high$14.26$8.64
52-week low$5.60$2.62
Distance from 52-week high-26.02%-35.65%
Analyst consensusbuystrong_buy
Avg. price target upside+32.70%+162.23%
Average volume3.53M1.38M
Shares outstanding218.31M103.10M
Employees2,63628
SectorHealth CareHealth Care
IndustryBiotechnology: In Vitro & In Vivo Diagnostic SubstancesBiotechnology: In Vitro & In Vivo Diagnostic Substances

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Neogen is about 4.0 times larger than Achieve Life Sciences by market value ($2.30B vs $573.25M).

About Neogen

NEOG stock →

Neogen Corporation develops, manufactures, and markets various products and services for food and animal safety in the United States and internationally. It operates through Food Safety and Animal Safety segments.

Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 2,636 employees

About Achieve Life Sciences

QUIT stock →

Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms.

Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 28 employees

NEOG vs QUIT FAQ

Which is bigger, Neogen or Achieve Life Sciences?

Neogen (NEOG) is larger, with a market capitalization of $2.30B compared with $573.25M for Achieve Life Sciences (QUIT).

Are Neogen and Achieve Life Sciences in the same industry?

Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.

More comparisons